Cargando…
The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary
SIMPLE SUMMARY: Few therapies are available for patients with aggressive or metastatic pituitary neuroendocrine tumours (PitNETs). Peptide receptor radionuclide therapy (PRRT), widely used to treat gastroenteropancreatic neuroendocrine tumours, has been emerging as a potential option for aggressive...
Autor principal: | Marques, Pedro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216433/ https://www.ncbi.nlm.nih.gov/pubmed/37345047 http://dx.doi.org/10.3390/cancers15102710 |
Ejemplares similares
-
Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
por: Elston, Marianne S., et al.
Publicado: (2021) -
Peptide Receptor Radionuclide Therapy
por: Hofland, Johannes, et al.
Publicado: (2022) -
Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience
por: Giuffrida, G, et al.
Publicado: (2019) -
Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary Carcinoma
por: Lin, Andrew L, et al.
Publicado: (2021) -
Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements
por: Merola, Elettra, et al.
Publicado: (2023)